Himmelreich Jeffrey C 4

What Happened Jeffrey C. Himmelreich, MAIA Biotechnology's Head of Finance, received a grant of 30,000 stock options on April 10, 2026. The Form 4 records the acquisition price as $0.00 (total $0, per the filing) and classifies the grant as a derivative award under MAIA's equity plan. This is an award/grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-04-10; Form 4 filed: 2026-04-14 (filed within required business days).
• Transaction type: Award/Grant of derivative security (stock options).
• Quantity: 30,000 options; price reported in filing: $0.00 (total $0 as reported).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote (vesting): Options vest over four years — 25% on the first anniversary of the grant, then monthly ratable vesting over the remaining 36 months (per footnote F1).
• No 10b5-1 plan, tax withholding, or late-filing flag noted in the provided information.

Context This grant gives Himmelreich the right to acquire underlying common shares if and when the options vest and are exercised; it does not represent an immediate purchase or sale of shares. Retail investors should note that option grants are commonly used for retention and compensation and do not by themselves indicate an insider is buying or selling stock in the open market. Watch for future filings showing exercises or sales if you want to track potential insider purchases or liquidity events.